Pregabalin Capsule 50mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.
MFDS item code 201907583 · Approved 2019.10.30
This product's status changed to Expired on 2024.10.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It also helps as an adjunct for partial seizures in epilepsy patients, with or without secondary general symptoms. Additionally, it is effective in treating fibromyalgia. This drug is used to improve symptoms in various nerve-related disorders.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of treatment.”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Initial dose (mg/day) | Maximum dose (mg/day) | Dosage regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosage regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.
This drug may increase the risk of suicidal thoughts or behaviors, so patients should immediately consult a physician if symptoms of depression, mood changes, or abnormal behaviors appear during treatment. Those who have hypersensitivity to this drug or specific genetic problems such as lactose intolerance should not use it. Diabetic patients should be cautious as weight gain may require adjustment of their blood sugar control medications. If symptoms of angioedema occur, discontinue use immediately and consult medical personnel. Elderly patients should be careful as dizziness or drowsiness may increase the risk of falls or injury. Temporary blurred vision or changes in vision may occur; symptoms should be reported. Abruptly stopping this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so dose adjustments should be made gradually according to a doctor's instructions. Due to the risk of drug abuse associated with this medication, patients with a history of substance abuse should use it with particular caution. Patients with impaired renal function may require dosage adjustments. Patients with severe heart disease should be cautious when using this drug. Combining this drug with other central nervous system depressants or alcohol may increase the risk of drowsiness or respiratory depression, so caution is necessary. During early pregnancy, there is a risk of fetal malformation, so pregnant women should refrain from using this drug, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should consult a physician regarding the possibility of this drug being transmitted through breast milk. Activities that require alertness, such as driving or operating machinery, should be avoided until dizziness or drowsiness resolves after taking this drug. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may occur, necessitating immediate medical attention. This medication should be kept out of reach of children, and it is safer not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 15 to 30 degrees Celsius to safely preserve the drug's effectiveness.
A hard capsule with a blue upper part and a white lower part containing white powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 50mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.